{ "schemaVersion": "gships-review-packet-1", "packetId": "opportunities:opp-argonne-cri-cohort-2027", "stableId": "opp-argonne-cri-cohort-2027", "family": "opportunities", "slug": "opp-argonne-cri-cohort-2027", "title": "Argonne Chain Reaction Innovations — Cohort 2027", "status": "prepared-human-review-not-started", "release": { "releaseId": "public-alpha-2026-07-26-research-visuals-r14", "sourceCommit": "3eb036fce3d711336c8c605625895e8a2e799ab0", "corpusGeneratedAt": "2026-07-25", "frozenAt": "2026-07-26T22:50:50.000Z", "canonicalOrigin": "https://gships.dammonburden.com" }, "paths": { "human": "/review/opportunities/opp-argonne-cri-cohort-2027", "family": "/review/opportunities", "packet": "/review-packets/opportunities/opp-argonne-cri-cohort-2027.089fd5a03a374995.json", "decisionTemplate": "/review-packets/opportunities/opp-argonne-cri-cohort-2027.089fd5a03a374995.decision-template.json", "worksheet": "/review-packets/opportunities/opp-argonne-cri-cohort-2027.089fd5a03a374995.worksheet.md", "byFingerprint": "/review-packets/by-fingerprint/089fd5a03a3749955a999f882e4cc10c33dc723316fb7897b549acf5a2bbcdbd.json" }, "boundary": "Prepared review packet; human review has not started. This packet is not a completed review, endorsement, reviewer appointment, partnership, or authorization to act.", "governingPolicies": [ { "id": "policy-editorial-governance-001", "version": "0.1.0", "path": "/editorial-policy", "recordType": "governing-policy", "fingerprint": "1f6a1f823e8bfe891b6a707c5dce2ee2337c0bb7d915b48d6060ca82b8da1b47", "snapshot": { "id": "policy-editorial-governance-001", "version": "0.1.0", "status": "foundation-policy-controls-not-yet-staffed", "adoptedForFoundation": "2026-07-25", "title": "Editorial governance and independent review", "publisher": "GShips Project", "maintainer": "Dammon Burden", "publisherInterest": "The maintainer intends to explore a commercial venture based on some GShips work. No entity, outside funding, customer, sponsor, or indexed-organization relationship currently exists.", "currentBoundary": "No independent domain reviewer or review council is currently appointed. Foundation records and outlines may not be represented as independently reviewed.", "reviewerSelection": [ "Publish the reviewer’s name, relevant credentials or lived expertise, review scope, compensation status, and declared conflicts with consent.", "Select for the actual claim domain rather than general prestige; include affected-community and disability-led expertise where rights or access are involved.", "Do not treat an employee, investor, customer, sponsor, source author, or directly supervised collaborator as independent for the affected claim." ], "reviewProcess": [ "Provide the exact claim, sources, locators, assumptions, counterevidence, transfer limits, and proposed evidence dimensions.", "Record approve, revise, contest, or reject at claim level; silence and event attendance never count as review.", "Publish material minority findings and the editor’s reasoned response.", "High-consequence medical, reproductive, nuclear, radiation, cybersecurity, governance, and dual-use claims require two qualified independent reviewers with complementary scopes.", "A reviewer may recuse at any time; unresolved conflicts or missing expertise block the reviewed label." ], "appealAndCorrection": [ "A correction receives a reference identifier and triage record; safety-critical allegations receive priority.", "A material editorial decision may be appealed to a reviewer not involved in the original decision once such a panel exists.", "Substantive reversals, unresolved disputes, and removed conclusions receive a dated public record that protects reporter privacy.", "No sponsor, customer, founder, or reviewer may purchase, suppress, or unilaterally assign an evidence grade." ], "publicationGate": "Public 1.0 requires named review coverage across every Academy track, documented high-consequence two-person review, a material-corrections log, reviewer conflict records, and an operating appeal path.", "correctionPath": "/corrections" } }, { "id": "policy-dual-use-001", "version": "0.1.0", "path": "/dual-use", "recordType": "governing-policy", "fingerprint": "81637e2849f9c0866d23f7174eb9a2ce522b86313167ebf5022fca122d6e506c", "snapshot": { "id": "policy-dual-use-001", "version": "0.1.0", "status": "planned-controls-not-yet-operational", "adoptedForFoundation": "2026-07-25", "title": "Civil, defensive, and rights-preserving use boundary", "summary": "GShips may research safety, resilience, logistics, communications, recovery, and cyber defense only within explicit end-use, rights, and independent-review controls. Calling an activity defensive is never sufficient by itself.", "scopeTrigger": "Apply dual-use review before accepting or materially advancing customer, funder, collaborator, operational, procurement, or publication-sensitive work whose capability, data, end use, or transfer could reasonably enable a prohibited use. Public non-actionable education still follows prohibited-content and sensitive-publication controls.", "allowedInPrinciple": [ "Safety engineering and independently assessed protection", "Resilience, graceful degradation, recovery, and disaster response", "Civil logistics, maintenance, communications, and knowledge continuity", "Cyber defense, secure software, incident response, and recovery", "Rights-preserving health, accessibility, ecology, education, and governance research" ], "prohibited": [ "Identification, tracking, prioritization, or engagement of people or assets for force, weapons, repression, or offensive operations; safety navigation, astronomy, collision avoidance, search and rescue, and independently governed planetary defense are not prohibited by this clause", "Weapons command-and-control or targeting support", "Offensive access, persistence, exploitation, or destructive cyber payloads", "Mass surveillance, biometric repression, or political-control systems", "Autonomous force application", "Coercive reproductive, medical, genetic, disability, or civic control", "Nonconsensual experimentation or treating residents as research instruments" ], "reviewRequiredBeforeAnyRelevantWork": [ "Customer, funder, collaborator, jurisdiction, beneficial-owner, and end-use screening", "Export-control and sanctions review by qualified counsel when applicable", "Written scope, allowed-use, prohibited-use, audit, termination, and incident clauses", "Independent stop-work authority with a named alternate and founder recusal", "Sensitive-publication and information-hazard review", "Whistleblowing, escalation, incident response, appeal, and anti-retaliation paths", "Aggregate transparency reporting that protects legitimate privacy and security" ], "currentBoundary": "No screening body, independent stop-work authority, contractual controls, or appeal body currently exists. Therefore no relevant customer, defense, dual-use, or operational engagement is authorized by this policy.", "changeControl": "Material changes require a dated public rationale, independent review, and may not be approved by the founder alone.", "correctionPath": "/corrections" } } ], "reviewContract": { "questions": [ { "id": "question-1", "text": "Does the official source support the opportunity identity, status, timing, eligibility, and access constraints?", "required": true }, { "id": "question-2", "text": "Is the proposed fit specific and proportionate without implying availability, invitation, selection, or funding?", "required": true }, { "id": "question-3", "text": "What deadline, rule, jurisdiction, cost, conflict, or accessibility fact would change the proposed next action?", "required": true } ], "exclusions": [ "Review does not submit, register, apply, contact, commit, purchase, or establish eligibility.", "Provider prestige and apparent fit cannot replace current official terms." ], "requestedScopeCodes": [ "ecosystem-due-diligence", "opportunity-eligibility-access" ], "dispositions": [ "approve", "revise", "contest", "reject", "recuse" ], "prohibitedInputs": [ "private legal names or contact details", "identity documents or raw credential files", "accessibility or medical records", "confidential conflict evidence", "classified, export-controlled, proprietary, or exploit material" ], "freshness": { "maximumDecisionAgeFromFreezeDays": 30, "eventOccurrenceRule": "Not applicable to this packet family." }, "completionRule": "Every primary record must receive the required number of valid, current-fingerprint approvals; every complementary scope group and required domain must be covered; any unresolved revise, contest, or reject disposition blocks publication.", "highConsequenceRule": "Named medical, reproductive, nuclear, radiation, cybersecurity, governance, and dual-use conclusions require two distinct qualified independent humans covering complementary domain-method and rights/public-interest scopes." }, "primaryRecords": [ { "recordType": "opportunity", "recordId": "opp-argonne-cri-cohort-2027", "title": "Argonne Chain Reaction Innovations — Cohort 2027", "publicPath": "/opportunities/opp-argonne-cri-cohort-2027", "recordFingerprint": "f2efe90c8f828db0e1e4bd35243b8365d2dca91cf5c438549bce9aa88f1f470e", "reviewRequirements": { "minimumIndependentApprovals": 1, "highConsequenceDomains": [], "requiredDomainCodes": [], "requiredComplementaryScopeGroups": [ { "id": "bounded-competence", "scopeClass": "bounded-competence", "oneOf": [ "ecosystem-due-diligence", "opportunity-eligibility-access" ] } ], "unresolvedNegativeFindingBlocksPublication": true, "currentUntil": "2026-08-02" }, "referenceIds": [], "snapshot": { "id": "opp-argonne-cri-cohort-2027", "name": "Argonne Chain Reaction Innovations — Cohort 2027", "url": "https://chainreaction.anl.gov/apply/", "provider": "Argonne National Laboratory Chain Reaction Innovations", "kind": "Laboratory-embedded entrepreneurship program", "timing": "The Cohort 2027 application is scheduled to open September 15 and close October 30, 2026 at 5 p.m. on the official page. The current page still labels the application closed because the 2026 cohort window has ended.", "fit": "Advanced materials, industrial efficiency, manufacturing digitization, advanced manufacturing, energy-water systems, computing, semiconductors, grids, storage, critical materials, recycling, buildings, scientific platforms, transport efficiency, and energy technology", "status": "forthcoming application window; not yet open", "verifiedAt": "2026-07-26", "currentUntil": "2026-08-02", "eligibility": "The official page says preferred applicants are technical founders with hands-on laboratory experience developing an early-stage innovation and that applicants must be U.S. citizens or lawful permanent residents when applying. Four yes-or-no eligibility questions, the forthcoming 2027 application, online portal, FAQ, appointment, laboratory, intellectual-property, safety, conflict, and program rules control actual eligibility.", "accessNotes": "CRI states that the two-year program includes a $115,000 annual stipend plus healthcare benefits, non-dilutive support, Argonne facilities and expertise, and business networks, and that Argonne and DOE take no startup equity. Those statements do not establish acceptance, total project funding, laboratory or equipment availability, intellectual-property terms, outside-work permissions, safety approval, incorporation needs, relocation, accessibility, or fit for a GShips product.", "founderAction": "Before the window opens, prepare only a no-application fit memo for a genuinely laboratory-dependent Earth-first technology, comparing CRI with non-laboratory and non-venture alternatives. Do not pre-apply, nominate, contact staff, incorporate, disclose confidential material, or imply Argonne or DOE support without separate authorization and independent eligibility, technical, intellectual-property, safety, conflict, budget, and civil-and-defensive review.", "evidenceBoundary": "Argonne's official application page supports the September 15–October 30, 2026 Cohort 2027 window, 5 p.m. close statement, U.S.-citizen or lawful-permanent-resident rule, preferred technical-founder profile, two-year duration, $115,000 annual stipend plus healthcare, stated non-dilutive support, no-equity statement, and listed priority areas. It does not establish application availability before September 15, a specific person's eligibility, acceptance, adequate funding, facility access, intellectual-property outcome, safety approval, accessibility, relocation, startup success, or relationship.", "relationship": "indexed only; no formal relationship", "actionStatus": "proposed; not undertaken", "conflicts": "Potential stipend, benefits, laboratory access, investor and corporate networks, public-laboratory reputation, technology and intellectual-property interests, relocation, selection, and the publisher's intended venture require independent review.", "whatWouldChange": "Publication of the Cohort 2027 application and eligibility questions, an opening or deadline change, updated stipend or benefit terms, an independent fit memo, or changed intellectual-property, safety, laboratory, conflict, appointment, access, or applicant rules would change this assessment." } } ], "linkedRecords": [], "referenceSnapshots": [ { "sourceId": "official-opportunity-opp-argonne-cri-cohort-2027", "sourceRecordType": "reference-source", "sourceFingerprint": "2cbef36760746426a53a95f5713574dbaf04f5382fc4dcdd2270260078f55278", "snapshot": { "title": "Argonne Chain Reaction Innovations — Cohort 2027", "url": "https://chainreaction.anl.gov/apply/", "checkedAt": "2026-07-26", "scopeNote": "Argonne's official application page supports the September 15–October 30, 2026 Cohort 2027 window, 5 p.m. close statement, U.S.-citizen or lawful-permanent-resident rule, preferred technical-founder profile, two-year duration, $115,000 annual stipend plus healthcare, stated non-dilutive support, no-equity statement, and listed priority areas. It does not establish application availability before September 15, a specific person's eligibility, acceptance, adequate funding, facility access, intellectual-property outcome, safety approval, accessibility, relocation, startup success, or relationship.", "subjectRecordType": "opportunity", "subjectRecordId": "opp-argonne-cri-cohort-2027" } } ], "packetFingerprint": "089fd5a03a3749955a999f882e4cc10c33dc723316fb7897b549acf5a2bbcdbd" }